Researchers discover treatable cause of severe anemia associated with a cancer therapy
Researchers at the Mount Sinai Tisch Cancer Center have identified that severe anemia in patients taking PARP inhibitors is often caused by folate deficiency rather than bone marrow suppression. This discovery suggests that routine screening and folic acid supplementation could prevent complications and treatment interruptions for cancer patients.
Why it matters
This finding offers a simple, low-cost intervention to improve the quality of life and treatment outcomes for patients undergoing targeted cancer therapies.
edited by Lisa Lock , reviewed by Andrew Zinin
The article reports on medical research findings in a factual, objective manner without political or social framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in